Acoramidis reduces cardiovascular mortality (CVM): results at month 42 from the ATTRibute-CM open-label extension (OLE) study

Back

ESC2025 Premium Access

Acoramidis reduces cardiovascular mortality (CVM): results at month 42 from the ATTRibute-CM open-label extension (OLE) study

Session: The evolving landscape of transthyretin amyloidosis

Topic: Infiltrative Myocardial Disease

Speaker: Assistant Professor K. Alexander (Palo Alto, US)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Assistant Professor Kevin Alexander

Stanford University School of Medicine, Palo Alto (United States of America)

0 follower

5 more presentations in this session

ATTRv longevity variant: a novel clinical entity in the spectrum of cardiac amyloidosis

Speaker: Doctor J. Costantino (Rome, IT)

Validation of red flags in cardiac amyloidosis across diagnostic modalities.

Speaker: Professor S. Spethmann (Berlin, DE)

Amyloid-specific medication in transthyretin amyloid cardiomyopathy: a systemic review and meta-analysis.

Speaker: Doctor M. Autherith (Vienna, AT)

Variant-specific differences in hereditary transthyretin cardiac amyloidosis

Speaker: Mr S. Muller (Utrecht, NL) Doctor M. Oerlemans (Utrecht, NL)

Renin-angiotensin-aldosterone system activity in transthyretin amyloid cardiomyopathy: implications for prognosis

Speaker: Doctor C. Kronberger (Vienna, AT)

Access the full session

The evolving landscape of transthyretin amyloidosis

Speakers: Assistant Professor K. Alexander, Doctor J. Costantino, Professor S. Spethmann, Doctor M. Autherith, Mr S. Muller...

Access

Video

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources